APPLICATION OF NIEMANN-PICK C1 PROTEIN IN DIAGNOSIS AND TREATMENT OF CANCER

WIPO Patent Application WO/2019/237688

A1

Disclosed in the present invention is a Niemann-Pick C1 protein (NPC1) and new use of a substance inhibiting NPC1 gene expression and/or protein activity, selected from at least one of the following: (a) used for preparing a kit for diagnosis of liver cancer; (b) used for preparing a kit for prognosis of liver cancer; (c) used for preparing a companion diagnostic kit for treatment of liver cancer; (d) used for preparing a drug for preventing and/or treating a cancer; (e) used for preparing a drug for preventing and/or treating diffusion transfer of a cancer; (f) used for preparing a drug for promoting apoptosis of cancer cells; (g) used for preparing a drug for inhibiting cancer cells from developing into a cancer; and (h) used for preparing a drug for inhibiting in-vitro proliferation of cancer cells. Experiments prove that NPC1 is obviously highly expressed in a liver cancer tissue and a serum, the high abundance of NPC1 prompts that the prognosis of a liver cancer patient is poor, and NPC1 can be used as a marker of early diagnosis, prognosis, or diagnosis and treatment guidance of tumors, in particular, liver cancer, independently or in combination with other proteins. An NPC1 inhibitor can be used as a candidate drug target of tumors, in particular, liver cancer.

JIANG YING (CN)
SUN AIHUA (CN)
HE FUCHU (CN)
LI CHAOYING (CN)
ZHOU JINAN (CN)
WEI HANDONG (CN)

PCT/CN2018/120034

December 19, 2019

December 10, 2018

Click for automatic bibliography generation  

BEIJING PROTEOME RES CENTER (CN)

C12N5/00; A61P35/00; C12Q1/68

CN1852974A	2006-10-25
CN103642927A	2014-03-19
US20100004190A1	2010-01-07

JEEKAI & PARTNERS (CN)

View/Download PDF      PDF Help

Previous Patent: STYLUS BODY EJECTION STRUCTURE, STYLUS AND ELECTRONIC DEVICE

Next Patent: PUMP ASSEMBLY AND DISHWASHER